Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
May 17 2017 - 8:27PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”)
today announced that an abstract and poster have been accepted for
presentation at the American Society of Clinical Oncology (ASCO)
53rd annual meeting to be held in Chicago, Illinois, 2-6 June 2017.
The poster presentation, entitled “Combination of
paclitaxel and LAG-3Ig (IMP321), a novel MHC class II agonist, as a
first-line chemoimmunotherapy in patients with metastatic breast
carcinoma (MBC): Interim results from the run-in phase of a placebo
controlled randomized phase II” will be presented by lead author,
Dr Francois P. Duhoux from Université Catholique de Louvain,
Cliniques universitaires Saint-Luc, Brussels, Belgium.
It will provide initial safety, immune-monitoring
and activity results of the 15 patient safety run-in phase of
Prima’s AIPAC clinical trial for patients with hormone receptor
positive (HR+) MBC combining IMP321 with first-line weekly
paclitaxel.
The poster presentation will take place from 8:00am
to 11:30am on Sunday, 4 June in Hall A. The shorter abstract
(number 1062), just containing safety data, is available on the
meeting website at http://am.asco.org/abstracts.
The full poster presentation will be available from
Monday 5 June, with a link provided on the Prima BioMed website –
www.primabiomed.com.au
About AIPAC (Active Immunotherapy PAClitaxel)
AIPAC is the acronym for Prima’s multicentre, Phase IIb,
randomised, double-blind, placebo-controlled study in hormone
receptor-positive metastatic breast carcinoma patients receiving
IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a
standard chemotherapy treatment regimen of paclitaxel. The primary
purpose of the AIPAC trial is to determine the clinical benefit of
IMP321 in terms of Progression-Free Survival as the primary
clinical endpoint in this patient population. The study consists of
two parts: a safety run-in phase (15 patients) and a randomized and
controlled phase (226 patients). Details of the AIPC study are
posted on www.clinicaltrials.gov (clinicaltrials.gov identifier NCT
02614833).
About Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Apr 2023 to Apr 2024